ArticlePloS one2016
Early Change in Metabolic Tumor Heterogeneity during Chemoradiotherapy and Its Prognostic Value for Patients with Locally Advanced Non-Small Cell Lung Cancer.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Predictive and prognostic value of tumor volume and its changes during radical radiotherapy of stage III non-small cell lung cancer : A systematic review.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2018Pooled it
- Clinical applications of textural analysis in non-small cell lung cancer.The British journal of radiology · 2018Pooled it
- Role of interimEuropean journal of nuclear medicine and molecular imaging · 2017Pooled it
- Immediate post-microwave ablation computed tomography model may better predict short-term response of stage I non-small cell lung cancer.World journal of radiology · 2026Article
- A narrative review of imaging intratumor heterogeneity in non-small cell lung cancer: current advances.Translational lung cancer research · 2025Review
- CT-Based Radiomics forCancers · 2025Article
- Mid-treatment changes in intra-tumoural metabolic heterogeneity correlate to outcomes in oropharyngeal squamous cell carcinoma patients.EJNMMI research · 2025Article
- PET radiomics in lung cancer: advances and translational challenges.EJNMMI physics · 2024Review
- Coefficient of variation and texture analysis of 18F-FDG PET/CT images for the prediction of outcome in patients with multiple myeloma.Annals of hematology · 2024Article
- Machine learning-based analysis ofPhysical and engineering sciences in medicine · 2024Article
- Heterogeneity of Glycolytic Phenotype Determined byDiagnostics (Basel, Switzerland) · 2023Article
- A nomogram based onQuantitative imaging in medicine and surgery · 2022Article
- Article
- Radiomics in Oncological PET Imaging: A Systematic Review-Part 1, Supradiaphragmatic Cancers.Diagnostics (Basel, Switzerland) · 2022Review
- Radiomics as a New Frontier of Imaging for Cancer Prognosis: A Narrative Review.Diagnostics (Basel, Switzerland) · 2021Review
- Prognostic Value of Computed Tomography and/orClinical lung cancer · 2021Article
- Incorporating radiomics into clinical trials: expert consensus endorsed by the European Society of Radiology on considerations for data-driven compared to biologically driven quantitative biomarkers.European radiology · 2021Article
- Is FDG-PET texture analysis related to intratumor biological heterogeneity in lung cancer?European radiology · 2021Article
- A Systematic Review of PET Textural Analysis and Radiomics in Cancer.Diagnostics (Basel, Switzerland) · 2021Review
- FDG-PET Radiomics for Response Monitoring in Non-Small-Cell Lung Cancer Treated with Radiation Therapy.Cancers · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTo observe the early change of metabolic tumor heterogeneity during chemoradiotherapy and to determine its prognostic value for patients with locally advanced non-small cell lung cancer (NSCLC).
methodsFrom January 2007 to March 2010, 58 patients with NSCLC were included who were received 18F-fluorodeoxyglucose (18F-FDG) PET/CT before and following 40 Gy radiotherapy with the concurrent cisplatin-based chemotherapy (CCRT). Primary tumor FDG uptake heterogeneity was determined using global and local scale textural features extracted from standardized uptake value (SUV) histogram analysis (coefficient of variation [COV], skewness, kurtosis, area under the curve of the cumulative SUV histogram [AUC-CSH]) and normalized gray-level co-occurrence matrix (contrast, dissimilarity, entropy, homogeneity). SUVmax and metabolic tumor volume (MTV) were also evaluated. Correlations were analyzed between parameters on baseline or during treatments with tumor response, progression-free survival (PFS), and overall survival (OS).
resultsCompared with non-responders, responders showed significantly greater pre-treatment COV, contrast and MTV (AUC = 0.781, 0.804, 0.686, respectively). Receiver-operating-characteristic curve analysis showed that early change of tumor textural analysis serves as a response predictor with higher sensitivity (73.2%~92.1%) and specificity (80.0%~83.6%) than baseline parameters. Change in AUC-CSH and dissimilarity during CCRT could also predict response with optimal cut-off values (33.0% and 28.7%, respectively). The patients with greater changes in contrast and AUC-CSH had significantly higher 5-year OS (P = 0.008, P = 0.034) and PFS (P = 0.007, P = 0.039). In multivariate analysis, only change in contrast was found as the independent prognostic factor of PFS (HR 0.476, P = 0.021) and OS (HR 0.519, P = 0.015).
conclusionsThe metabolic tumor heterogeneity change during CCRT characterized by global and local scale textural features may be valuable for predicting treatment response and survival for patients with locally advanced NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.